Vagulienė, N. “THE PEMBREIZH MULTICENTER REAL-LIFE COHORT STUDY: FIRST LINE PEMBROLIZUMAB FOR NON-SMALL CELL LUNG CANCER PATIENTS WITH PD-L1 ≥50%”. Pulmonology and Allergology, Vol. 4, no. 2, Sept. 2020, pp. 164-7, doi:10.37499/PIA.119.